Olink Target 96 Immune Response Panel

What is the Olink Target 96 Immune Response Panel

Customized panel for human

The Olink Target 96 Immune Response panel enables simultaneous quantification of up to 92 proteins across 88 samples using only 1 µL of sample volume per assay. Data are delivered in normalized protein expression (NPX) units, offering precise insights into relative protein abundance. The system features 15 strategically curated panels designed to minimize target overlap, allowing researchers to flexibly combine multiple panels for enhanced proteome coverage. This modular design supports tailored experimental configurations, empowering comprehensive and customizable protein profiling to address diverse research needs.

Features of the pane

• Species: Primarily validated for human proteins; cross-reactivity with other species is not guaranteed.
• Proteins: Simultaneously analyze 92 protein biomarkers.
• Sample: Requires only 1µL of plasma, serum & more
• Readout: Data are delivered in normalized protein expression (NPX) units, offering precise insights into relative protein abundance.
• Platform: The panel is designed to run on the Olink Signature Q100 system.

List of 92 human derived biomarkers

Protein category

The Olink Target 96 Immune Response Panel includes 92 proteins categorized into nine main groups: the enzymes (18), receptors (21), Cytokines/Chemokines (8), Structural/Cell Adhesion (10), Transcription Factors/Regulators (8), Signaling Proteins (12), Immune-Related (10), Apoptosis (2) and other functional proteins (3), encompassing the immunoglobulin receptor superfamily, interferon family, growth factors, and intercellular signaling molecules. This extensive coverage of human immune system proteins makes the panel an essential tool for advanced disease modeling, longitudinal studies, and translational research.

Table. List of Olink Target 96 Immune Response panel

Protein Functions

Biological process

Primarily associated with Viral defense responses, lymphocyte activation, inflammatory responses, and cytokine-mediated signaling pathways.

Disease area

Primarily associated with autoimmune diseases, immuno-oncology,

Workflow of Olink Proteomics

Demo Results of Olink Data

(Figures come from Ding, R., et al. 2024)

The bar chart displayed the number of proteins.

Volcano plots of differentially expressed proteins.

Heatmap of differentially expressed proteins.

Case Study

Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma

Journal: ESMO Open
Year: 2024

• Background
• Results

Pancreatic ductal adenocarcinoma (PDAC) patients often show limited response to immune checkpoint inhibitors. However, the CheckPAC phase II trial (NCT02866383) demonstrated promising outcomes, with a 37% clinical benefit rate and a 14% response rate in metastatic PDAC patients treated with stereotactic radiation therapy combined with nivolumab, with or without ipilimumab. To identify biomarkers predictive of treatment response, translational studies were conducted. This study analyzed the association between treatment outcomes and 92 circulating immuno-oncology-related proteins in CheckPAC trial participants, aiming to characterize patients who may benefit from this therapeutic approach and uncover potential predictive biomarkers for improved PDAC management.

Elevated Fas ligand (FASLG) and galectin-1 (Gal-1) levels, coupled with reduced C-C motif chemokine 4 (CCL4), correlated with clinical benefit (CB). Univariable analysis associated high FASLG and Gal-1 with prolonged progression-free survival (PFS), though only Gal-1 retained significance in multivariable Cox regression (P < 0.001 vs. FASLG, P = 0.06). Unsupervised clustering of T-cell activation and immune checkpoint-related proteins identified patient clusters with higher CB rates and elevated tumor expression of leukocyte/T-cell markers (CD3, CD45, granzyme B). Immunotherapy triggered significant increases in 36 proteins, including FASLG, immune checkpoint proteins, and activation markers. Notably, these elevations occurred irrespective of treatment response but were absent in chemotherapy-treated cohorts, highlighting distinct immune-modulatory effects of immunotherapy independent of clinical outcomes.

Figure 1. box plots showing protein levels as normalized protein expression (NPX) for patients with CB and no CB for the three proteins.using the Olink platform. (T D Christensen, et al. 2024)

FAQs

Why Creative Proteomics

Comprehensive Bioinformatics Support

Expert bioinformatics teams deliver customized Olink data analysis, uncovering immune mechanisms and biological processes with advanced computational tools.

Broad Applications in Scientific Research

Services support diverse research needs, including disease modeling, biomarker discovery, and translational studies across immunology, oncology, and neurology.

Efficient Workflow

State-of-the-art platforms and standardized protocols ensure accurate, high-throughput, and reproducible results with rapid turnaround times.

Industry-Leading Customer Support

End-to-end assistance, technical guidance, and access to resources like tutorials and expert consultations ensure seamless research experiences.

Sample Requirements

References

1. Christensen, T. D., Maag, E.et al. (2024). Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma. ESMO open, 9(6), 103489. https://doi.org/10.1016/j.esmoop.2024.103489
2. Ding, R., Wu, L., Wei, S., et al. (2024). Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage. Proteome science, 22(1), 11. https://doi.org/10.1186/s12953-024-00236-x
3. Kugler, S., Hahnefeld, L., et al. (2024). Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units. Talanta, 268(Pt 1), 125295. https://doi.org/10.1016/j.talanta.2023.125295